새로운 심부전 약제, SGLT2 억제제
SGLT2 Inhibitors: Emerging Drugs in Heart Failure
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of diabetes medications that have demonstrated the potential to improve outcomes for heart failure (HF) patients. Although they were originally developed to treat diabetes, clinical trials have demonstrated their ability to both reduce the risk and improve the prognosis of HF. SGLT2 inhibitors have unique mechanisms of action, including improvement of water retention and promotion of lipolysis, which contribute to their effectiveness in treating HF. They are considered essential primary treatment options for patients with HF, regardless of diabetes status and ejection fraction. Overall, the use of SGLT2 inhibitors in patients with HF is expected to increase in the future and may further improve treatment outcomes for HF patients.
Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute a class of diabetes medications that have demonstrated the potential to improve outcomes for heart failure (HF) patients. Although they were originally developed to treat diabetes, clinical trials have demonstrated their ability to both reduce the risk and improve the prognosis of HF. SGLT2 inhibitors have unique mechanisms of action, including improvement of water retention and promotion of lipolysis, which contribute to their effectiveness in treating HF. They are considered essential primary treatment options for patients with HF, regardless of diabetes status and ejection fraction. Overall, the use of SGLT2 inhibitors in patients with HF is expected to increase in the future and may further improve treatment outcomes for HF patients.
참고문헌 (19)
- Cho DH, "Temporal trends in heart failure over 11 years in the aging Korean population : a retrospective study using the national health insurance database", PLoS One, 17, pp.e0279541~ (2022)
- McMurray JJ, "Angiotensin-neprilysin inhibition versus enalapril in heart failure", N Engl J Med, 371, pp.993~1004 (2014)
- Zinman B, "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes", N Engl J Med, 373, pp.2117~2128 (2015)
- Wiviott SD, "Dapagliflozin and cardiovascular outcomes in type 2 diabetes", N Engl J Med, 380, pp.347~357 (2019)
- McMurray JJV, "Dapagliflozin in patients with heart failure and reduced ejection fraction", N Engl J Med, 381, pp.1995~2008 (2019)
- Packer M, "Cardiovascular and renal outcomes with empagliflozin in heart failure", N Engl J Med, 383, pp.1413~1424 (2020)
- McDonagh TA, "2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure", Eur Heart J, 42, pp.3599~3726 (2021)
- Cho DH, "Current prevalence, incidence, and outcomes of heart failure with preserved ejection fraction", Heart Fail Clin, 17, pp.315~326 (2021)
- Anker SD, "Empagliflozin in heart failure with a preserved ejection fraction", N Engl J Med, 385, pp.1451~1461 (2021)
- Solomon SD, "Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction", N Engl J Med, 387, pp.1089~1098 (2022)
- Verma S, "SGLT2 inhibitors and mechanisms of cardiovascular benefit : a state-of-the-art review", Diabetologia, 61, pp.2108~2117 (2018)
- Inzucchi SE, "How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG outcome trial", Diabetes Care, 41, pp.356~363 (2018)
- Tobita H, "Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus : a prospective, open-label, uncontrolled study", Curr Ther Res Clin Exp, 87, pp.13~19 (2017)
- Santos-Gallego CG, "Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics", J Am Coll Cardiol, 73, pp.1931~1944 (2019)
- Kim SR, "SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease", Nat Commun, 11, pp.2127~ (2020)
- Gaborit B, "Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes : the EMPACEF study", Cardiovasc Diabetol, 20, pp.57~ (2021)
- Hundertmark MJ, "Design and rationale of the EMPA-VISION trial : investigating the metabolic effects of empagliflozin in patients with heart failure", ESC Heart Fail, 8, pp.2580~2590 (2021)
- Yurista SR, "Therapeutic potential of ketone bodies for patients with cardiovascular disease : JACC state-of-the-art review", J Am Coll Cardiol, 77, pp.1660~1669 (2021)
- Braunwald E, "SGLT2 inhibitors : the statins of the 21st century", Eur Heart J, 43, pp.1029~1030 (2022)